CDT Equity Inc.
CDTHealthcare|Biotechnology|US
$1.31
+0.46 (+54.85%)
Graham Number
$3161.02
Cash / Share
$654.14
Financials
Financial Snapshot
Market Cap
$610.6K
Enterprise Value
$971.2M
Revenue (TTM)
$1.45B
Net Income (TTM)
$91.1M
Cash & Investments
$348.7M
Net Cash
-$970.6M
Free Cash Flow (TTM)
-$1.3M
Operating CF (TTM)
$124.4M
Debt/Equity
0.95
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Cash & Investments | $48.6K | $0.00 | $4.2M | $554.0K | $389.9M | $348.7M | |
| Operating Cash Flow | -$2.2M | -$2.3M | -$7.7M | -$9.7M | -$15.6M | $124.4M | |
| Free Cash Flow | -$2.2M | -$2.3M | -$7.7M | -$9.7M | -$18.0M | -$1.3M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | -$51.0K | -$2.4M | -$125.7M | |
| Financing Cash Flow | $1.9M | $2.4M | $10.9M | $6.1M | $17.4M | -$85.8M |
R&D Spending
R&D (TTM)
$65.3M
R&D Intensity
4.5%
R&D Growth vs Prior
+1191.5%
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.45B | |
| R&D Expense | $283.0K | $111.0K | $90.0K | $3.4M | $5.1M | $65.3M | |
| R&D % of Revenue | — | — | — | — | — | 4.5% | |
| SG&A | $2.9M | $3.0M | $5.2M | $12.0M | $31.7M | $167.3M |
Income Statement
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.45B | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $887.4M | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $559.1M | |
| R&D | $283.0K | $111.0K | $90.0K | $3.4M | $5.1M | $65.3M | |
| SG&A | $2.9M | $3.0M | $5.2M | $12.0M | $31.7M | $167.3M | |
| Operating Income | -$3.2M | -$3.2M | -$5.3M | -$15.4M | -$36.8M | $167.1M | |
| Interest Expense | $0.00 | $0.00 | $211.0K | $1.5M | $319.0K | -$27.0M | |
| Pretax Income | -$3.7M | -$4.9M | $2.8M | -$17.8M | -$39.2M | $119.5M | |
| Net Income | -$3.7M | -$4.9M | -$535.0K | -$17.8M | -$39.2M | $91.1M | |
| EPS (Diluted) | -750.00 | -201360.00 | -267600.00 | -615930.00 | -11778.00 | -5669.00 | |
| EBITDA | -$3.7M | -$4.9M | $3.1M | -$15.8M | -$36.5M | $211.3M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.53 |
Balance Sheet
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $48.6K | $0.00 | $4.2M | $554.0K | $389.9M | $348.7M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $104.2K | $0.00 | $5.7M | $2.7M | $1.35B | $1.39B | |
| Total Assets | $213.1K | $5.0K | $7.2M | $4.2M | $3.54B | $3.50B | |
| Total Current Liabilities | $192.5K | $4.2M | $1.8M | $10.7M | $697.5M | $652.8M | |
| Long-Term Debt | $0.00 | $1.8M | $0.00 | $0.00 | $1.29B | $1.32B | |
| Total Liabilities | $192.5K | $10.1M | $7.7M | $11.0M | $2.28B | $2.12B | |
| Stockholders' Equity | $20.6K | -$10.1M | -$457.0K | -$6.8M | $1.26B | $1.38B | |
| Retained Earnings | -$4.4K | -$10.8M | -$11.3M | -$29.1M | $1.41B | $1.52B |
Cash Flow Statement
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.2M | -$2.3M | -$7.7M | -$9.7M | -$15.6M | $124.4M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | -$51.0K | -$2.4M | -$125.7M | |
| Free Cash Flow | -$2.2M | -$2.3M | -$7.7M | -$9.7M | -$18.0M | -$1.3M | |
| Investing Cash Flow | $0.00 | -$183.0K | $725.0K | -$43.0K | -$808.0K | -$124.3M | |
| Financing Cash Flow | $1.9M | $2.4M | $10.9M | $6.1M | $17.4M | -$85.8M | |
| Issuance of Stock | $1.2M | $1.3M | $150.0K | $3.3M | $19.7M | $12.4M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | -$106.0K | $0.00 | |
| Net Debt Issuance | $688.0K | $1.1M | $2.3M | $2.5M | -$2.2M | $1.4M | |
| Stock Based Comp. | $0.00 | $0.00 | $199.0K | $1.6M | $2.2M | $40.3M | |
| Net Change in Cash | -$252.0K | $0.00 | $4.2M | -$3.7M | $955.0K | -$86.9M |
Dilution Tracker
Shares outstanding grew 57694.9% over 5 years — significant dilution
Shares Outstanding
0M
5-Year Share Growth
+57694.9%
Stock Issuance (TTM)
$12.4M
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.53 | |
| Change vs Prior % | — | 316.5% | -4.2% | 26.1% | 11382.8% | 15906.0% | |
| Stock Issuance | $1.2M | $1.3M | $150.0K | $3.3M | $19.7M | $12.4M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | -$106.0K | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $199.0K | $1.6M | $2.2M | $40.3M |
Margins & Profitability
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | — | — | 38.7% | |
| Operating Margin % | — | — | — | — | — | 11.6% | |
| Net Margin % | — | — | — | — | — | 6.3% | |
| EBITDA Margin % | — | — | — | — | — | 14.6% | |
| FCF Margin % | — | — | — | — | — | -0.1% | |
| ROE % | -17736.1% | 48.4% | 117.1% | 262.1% | -3.1% | 9.3% | |
| ROA % | -1715.9% | -97740.0% | -7.4% | -424.6% | -1.1% | 2.6% | |
| ROIC % | -1605.2% | 79.1% | -82.1% | -1922.6% | -1.3% | 4.5% | |
| R&D / Revenue % | — | — | — | — | — | 4.5% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | 0.4% | -66.5% | -193.0% | -138.4% | |
| Net Income | 0.0% | -33.6% | 89.1% | -3227.5% | -120.3% | |
| EPS (Diluted) | 0.0% | -26748.0% | -32.9% | -130.2% | 98.1% | |
| Operating Cash Flow | 0.0% | -5.3% | -240.9% | -25.3% | -60.7% | |
| Free Cash Flow | 0.0% | -5.3% | -240.9% | -26.0% | -84.5% | |
| R&D Expense | 0.0% | -60.8% | -18.9% | 3653.3% | 49.6% | |
| SG&A Expense | 0.0% | 5.5% | 69.6% | 132.8% | 163.3% | |
| Total Assets | 0.0% | -97.7% | 144380.0% | -42.0% | 84412.8% | |
| Book Value / Share | 0.0% | -11846.9% | 95.1% | -1027.6% | 262.1% | |
| Debt | 0.0% | 1035.2% | -51.0% | 657.1% | 17141.1% | |
| Diluted Shares | 0.0% | 316.5% | -4.2% | 26.1% | 11382.8% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.00
EV/EBITDA4.60
EV/Revenue0.67
P/FCFAt Loss
Intrinsic Value Models (per share)
Graham Number
$3161.02
Cash / Share
$654.14
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| P/E Ratio | -20760208.00 | -77324.97 | -284733.75 | -167.07 | -13.58 | -0.00 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 4350906.75 | -37038.73 | -328559.07 | -439.29 | 0.42 | 0.00 | |
| EV/EBITDA | -24531.44 | -76465.27 | 49180.56 | -188.84 | -39.16 | 4.60 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.67 |
Analyst Estimates & Quality
Altman Z-Score
1.44
Distress
Piotroski F-Score
7
Strong
Revenue Segments
By Product
| Segment | 2024 |
|---|---|
| Automation Solutions | $1.32B |
By Geography
| Segment | 2024 |
|---|---|
| CANADA | $160.0M |
| CHINA | $92.1M |
| GERMANY | $118.3M |
| Other Countries | $698.3M |
| UNITED STATES | $1.39B |